Effect of penbutolol (Hoe 893 d) and practolol on exercise-induced angina pectoris 2 and 24 hours after a signle oral dose

Westheim, A.S.; Christensen, C.C.; Kjekshus, J.

European Journal of Clinical Pharmacology 13(3): 157-162


ISSN/ISBN: 0031-6970
PMID: 27370
DOI: 10.1007/bf00609977
Accession: 068518411

Download citation:  

Article/Abstract emailed within 0-6 h
Payments are secure & encrypted
Powered by Stripe
Powered by PayPal

The effect of penbutolol (Hoe 893 d), a new non-cardioselective .beta.-blocking agent presumed to have a prolonged action, was compared with practolol and placebo by exercise tests in 12 male patients with stable angina pectoris. The patients received oral penbutolol 20 mg, practolol 200 mg or placebo in a randomized, double blind, cross-over trial. The preparations of penbutolol 10 mg, practolol 100 mg and placebo were in identical-appearing capsules. Exercise tests were performed after 2 and 24 h. In the tests performed after 2 h, both .beta.-blockers increased the total work performed and the duration of work significantly more than placebo (P < 0.05). Penbutolol increased the exercise period before appearance of angina pectoris from 4.6 to 7.1 min (P < 0.05). The difference between practolol and placebo was not significant. The rate pressure product was significantly reduced aften penbutolol compared to placebo (P < 0.05). At the amount of work that forced patients on placebo to stop, the ST-depression in the ECG was significantly reduced after .beta.-blocker (P < 0.05). At maximum work load no significant difference between the .beta.-blockers and placebo was found. After 24 h virtually no clinical effects were observed after either penbutolol or practolol. One patient on practolol complained of Raynaud's syndrome. No side effects were noted after penbutolol.